Compare ADMA Biologics Inc (ADMA) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Fastly Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Fastly Inc trades at $19.33 (market cap $2.91B). The key difference: Fastly Inc is the larger of the two by market cap, and Fastly Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | FSLY | |
|---|---|---|
Market Cap | $2.13B | $2.91B |
Sector | Health | Technology |
52-Week High | $20.38 | $33.50 |
52-Week Low | $7.60 | $6.36 |
Enterprise Value | $2.20B | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Fastly (FSLY) trades at $18.59, up 2.54% with a bullish technical signal and positive earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows improving revenue growth (20% YoY in Q1 2026) and margin expansion, though it remains unprofitable with a -15.79% net income margin. Recent positive developments include Gartner recognition and strategic AI partnerships, while analyst consensus leans neutral with a $25.80 price target representing 39% upside potential.
Fastly presents a growth opportunity in edge cloud infrastructure with strong AI-driven demand, but carries execution risks amid ongoing losses. The stock's valuation at 4.18x sales appears reasonable for a 20% grower, though competitive pressures and high infrastructure spending require careful monitoring. Current technical strength near key support at $18 suggests near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
